Replies to post #2387 on Enanta Pharmaceuticals Inc (ENTA)

[biocqr]

Thanks. How concerning is the possibility of protease mutations that would diminish EDP-235 efficacy?

Impact of SARS-CoV-2 3CL Protease Mutations on Nirmatrelvir Inhibitory Efficiency. Computational Insights into Potential Resistance Mechanisms